Unflame

Psoriasis · Pattern story 01

Why psoriasis comes back in the same spot

A plaque fades, the skin looks normal for months, then the same elbow flares again. The skin has not forgotten. But the 'memory' is only part of the story, and the number you may have read online is wrong.

By Laxmanna · Updated 2026-10-21 · 7 min read · 16 sources

60%

of relapsing plaque area returned inside old plaque borders in the only body-mapping study; about 40% appeared on previously clear skin.[1]

5–16×

more tissue-resident memory T cells in cleared psoriasis skin than in healthy skin, after phototherapy and biologics respectively.[2]

1–3 weeks

typical delay between a skin injury and a new plaque at that site (the Koebner phenomenon). Most injuries do not produce one; about a third of adults recall it ever happening.[14]

What 'cleared' skin is hiding

When a psoriasis plaque resolves, the redness and scale go, but the tissue underneath does not fully return to normal. Biopsies of skin that scored as completely clear still contain a dense pocket of tissue-resident memory T cells, a type of immune cell that parks itself in a tissue and stays there. In one study these cells were about five times more abundant in cleared psoriasis skin than in healthy skin after phototherapy; in another, after biologic treatment, the enrichment was closer to sixteen-fold.[2][3]

Those cells are not inert. When taken out of cleared skin and stimulated in the laboratory, they can still produce interleukin-17A, one of the main inflammatory signals in psoriasis.[3] Genetic sequencing of cleared lesions found that a fraction of the specific T-cell clones that drove the original plaque, roughly 7% in one study, stayed parked at the same site.[3] Alongside the cells there is what researchers call a molecular scar: more than 200 genes in resolved lesions failed to return to the levels seen in healthy skin even after months of effective treatment.[4]

Visible clearance is not biological clearance. The surface can look identical to healthy skin while the tissue underneath keeps a footprint of the last flare.[2][3][4]

These are small human biopsy studies, and the laboratory stimulation tests show what cells are capable of, not that they are continuously active in your skin. The direction of the finding is consistent across studies; the exact numbers are not precise.

Who holds the memory

Resident memory T cells are the best-studied candidate, and in mouse models they are sufficient to re-create a plaque: grafting human cleared skin onto mice, or re-challenging mice after a first flare, brings psoriasis-like inflammation back at the old site.[5] But human tissue memory looks more like an ensemble than a soloist. Dermal fibroblasts in resolved skin keep an active IL-17 signalling programme.[6] Langerhans cells, the skin's resident antigen-presenting cells, keep high expression of IL-23.[7] Even the keratinocytes, the ordinary skin cells, carry epigenetic marks on their DNA that distinguish resolved skin from skin that was never involved.[8]

There is also evidence that 'never-affected' skin in people with psoriasis is not quite the same as healthy skin: it is immunologically primed compared with skin from people without the condition.[8] That helps explain why plaques can appear in new places at all.

Direct cause-and-effect proof, where you remove one cell type and the memory disappears, exists only in mice. In humans the evidence is correlation from biopsies. That is normal for this kind of question, but it is worth knowing which is which.

The 90% figure, traced

You may have read that 90% of psoriasis flares return to the exact same spot. Following that number back through the literature, it comes from a 2020 narrative review that attributes it to 'unpublished data' from one of the authors, with no patient count, no method and no mapping.[9] It has been repeated since as if it were an established finding.

The only study that objectively mapped the whole body before and after relapse followed people through Dead Sea climatotherapy and then photographed their skin as plaques returned. On average, 60.2% of the new plaque area fell inside the borders of the old plaques. The remaining 39.8% appeared on skin that had been clear. Overlap ranged from 35% to 94% between individuals.[1]

ClaimWhere it comes fromWhat it rests on
"90% return to the same spot"2020 narrative review citing unpublished data[9]No denominator, no mapping method
"About 60% return inside old borders; about 40% are new skin"Prospective total-body photo mapping after climatotherapy[1]Small cohort; scalp, hands, feet and skin folds excluded

So the honest version is: same-site recurrence is real and biologically grounded, but it is a strong tendency, not a rule.

What actually wakes a flare

A primed patch of skin needs something to tip it over. In the trial data, the single most predictable driver of relapse is stopping treatment. When people on a biologic were switched to placebo in a randomised withdrawal study, the median time to losing disease control was about 15 weeks, and relapse eventually occurred in most people after treatment was withdrawn.[11][10][12] How quickly it happened varied with the person: higher body-mass index, longer disease duration and prior biologic exposure were each associated with faster loss of response.[10][11]

Locally, injury matters. The Koebner phenomenon, where a cut, scratch, friction or sunburn produces a new plaque at that exact site one to three weeks later, is recalled by roughly a third of adults with psoriasis, though in controlled experiments most standardised injuries produce no plaque at all.[14] Importantly, it happens on skin that never had a plaque, which shows that local injury is a localising trigger in its own right, separate from site memory. We cover the Koebner evidence in detail here.

On the treatment side, drugs that block IL-23 have been shown to reduce the pool of resident memory T cells in skin, which is one reason they are being studied for longer drug-free remissions.[13][16] Lower counts have not yet been shown to mean permanent remission, and whether treating early can prevent the memory forming at all is an open question being tested in trials rather than a settled fact.[13][16]

What this means for you

  • A plaque that looks fully healed may still be a more sensitive patch of skin. That is biology, not a failure on your part.
  • Same-spot recurrence is a strong pattern, not a certainty. If a new patch appears somewhere new, it does not mean something unusual is happening.
  • Treatment changes, especially stopping, are the most predictable relapse trigger in the trial data. Any change is a conversation to have with your dermatologist first.
  • Protecting skin from injury, friction and sunburn is a concrete, low-risk thing you can do, because injury can seed plaques on both old and new skin.
  • If you log flares, note where they appear relative to old sites and what happened one to three weeks before. That is the window in which injury-related (Koebner) plaques show up.

Questions for your dermatologist

  1. Is my psoriasis currently classed as mild, moderate or severe, and does that change how it is monitored?
  2. Have I been screened for psoriatic arthritis this year? (Guidelines suggest an annual check, especially in the first 10 years.)
  3. If I am on a systemic or biologic treatment, what is the plan if I need to pause it, and what should I watch for?
  4. Does my body-mass index or disease duration change how my treatment is likely to hold?
  5. Are there sites on my body (scalp, nails, folds, face) that need a different approach?
  6. Is there anything about my work or sport that creates repeated friction or injury on the skin that flares?

When to seek care

Same-day emergency assessment is advised for widespread sterile pustules on red skin (generalised pustular psoriasis) or redness covering most of the body (erythroderma), particularly with fever, chills or feeling very unwell.[15] Ask for specialist referral if psoriasis covers a large area, involves the face, scalp, palms, soles, folds, genitals or nails, does not respond to topical treatment, or is causing significant distress.[15]

Guidelines also recommend that everyone with psoriasis is screened for psoriatic arthritis annually, and that people with severe disease have a cardiovascular risk check at diagnosis and every five years.[15]

Things people hear, and what the evidence says

"Psoriasis always comes back in exactly the same place."
In the only body-mapping study, about 60% of relapsing plaque area fell inside old borders and about 40% was on previously clear skin.[1]
"If the skin looks clear, the disease is gone."
Cleared skin keeps resident memory T cells, altered fibroblasts and a molecular scar of 200+ genes for months.[2][4][6]
"New biologics erase skin memory."
They reduce resident T-cell counts, but trial withdrawal arms still show relapse in most people over time. Permanent drug-free remission is a hypothesis under study, not a result.[11][13]
"There is a test that can predict where the next flare will be."
No clinical test predicts the site or timing of an individual flare.

Sources

Primary human studies are marked "primary"; reviews, guidelines and models are labelled. Where a source is an abstract only, that is stated.

  1. Emmanuel T et al. Non-random plaque-site recurrence of psoriasis in patients treated with Dead Sea climatotherapy. Acta Derm Venereol 2019 — primary. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3233
  2. Cheuk S et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 2014 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC3962894/
  3. Matos TR et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones. J Clin Invest 2017 — primary. https://www.jci.org/articles/view/93396
  4. Suárez-Fariñas M et al. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 2011 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC3021088/
  5. Whitley SK et al. Local IL-23 is required for proliferation and retention of skin-resident memory T cells. Sci Immunol 2022 — primary (mouse plus small human sample). https://pmc.ncbi.nlm.nih.gov/articles/PMC9847353/
  6. Single-cell analysis of psoriasis resolution: inflammatory fibroblast state persists in resolved skin. Nat Commun 2024 — primary. https://www.nature.com/articles/s41467-024-44994-w
  7. Martini E et al. Dynamic changes in resident and infiltrating epidermal dendritic cells in active and resolved psoriasis. J Invest Dermatol 2017 — abstract. https://pubmed.ncbi.nlm.nih.gov/28011143/
  8. Ghaffarinia A et al. Psoriatic resolved skin epidermal keratinocytes retain disease-residual transcriptomic and epigenomic profiles. Int J Mol Sci 2023 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC10002496/
  9. Chen L, Shen Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol 2020 — narrative review (origin of the 90% figure). https://pmc.ncbi.nlm.nih.gov/articles/PMC6952397/
  10. Lebwohl M et al. Investigation of plaque psoriasis relapse after secukinumab withdrawal. Clin Exp Dermatol 2024 — post hoc of randomised withdrawal. https://academic.oup.com/ced/article/49/8/793/7307582
  11. Kirby B et al. Time to loss of disease control after guselkumab withdrawal: VOYAGE 2. Dermatology 2024 — post hoc of phase 3 RCT. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965848/
  12. Kurihara K et al. IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis and clinical course. J Dermatol Sci 2019 — abstract. https://pubmed.ncbi.nlm.nih.gov/31300254/
  13. GUIDE part 2: 16-week vs 8-week guselkumab dosing with biopsy substudy. JAMA Dermatol 2024 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC11292573/
  14. Melski JW, Bernhard JD, Stern RS. The Koebner (isomorphic) response in psoriasis. Arch Dermatol 1983; and Kalayciyan A et al., experimental needle-prick study, Dermatology 2007 — primary. https://pubmed.ncbi.nlm.nih.gov/17684372/
  15. NICE CG153. Psoriasis: assessment and management — clinical guideline. https://www.nice.org.uk/guidance/cg153
  16. Jiang R et al. Longitudinal atlas of human psoriatic skin under anti-IL-23 therapy. Immunity 2026 — primary. https://pmc.ncbi.nlm.nih.gov/articles/PMC13293287/

Written by Laxmanna · Research-led health writer. Every explainer on Unflame starts from a structured evidence dossier: primary studies retrieved, claims tabulated, contradictions logged, and wording checked against what the sources can support. How the dossiers are built.

Related

Eczema · Psoriasis

The gut-skin axis is real. 'Your skin disease starts in your gut' is not what it shows.

Gut microbes, the intestinal barrier and circulating immune signals do communicate with the skin.

Read the explainer Psoriasis

Why a scratch can turn into a psoriasis plaque, and why most scratches don't

Skin injury can trigger a new psoriasis plaque at the exact site 1 to 3 weeks later.

Read the explainer